Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma 1Neoplasm Metastasis 1Endometrial Neoplasms 1

Interventions

Radiotherapy 11pembrolizumab 10Nivolumab 10Doxorubicin 10Magnetic Resonance Spectroscopy 9Specimen Handling 8Cyclophosphamide 8Biopsy 7X-Rays 6Ipilimumab 6Radiation 5Phantoms, Imaging 5Ifosfamide 5talimogene laherparepvec 4cabozantinib 4Nuclear Medicine Department, Hospital 4Irinotecan 4tazemetostat 3selpercatinib 3pazopanib 3liposomal doxorubicin 3fludarabine 3Temozolomide 3Etoposide 3ulixertinib 2tislelizumab 2tipifarnib 2palbociclib 2larotrectinib 2ivosidenib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Sarcoma × epacadostat × Clear all
NCT03414229 2026-04-23

A Study of Epacadostat, an IDO1 Inhibitor, in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
30 enrolled 11 charts
Sarcoma

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡